Relationship between serum and tear levels of tissue plasminogen activator and plasminogen activator inhibitor-1 in diabetic retinopathy

被引:4
|
作者
Jasmiad, Nurbadriah Binti [1 ]
Abd Ghani, Rohana Binti [1 ,2 ]
Agarwal, Renu [3 ]
Ismail, Zaliha Binti [4 ]
Abdullah, Azlindarita Aisyah Mohd [5 ,6 ]
Idorus, Mohd Yusri [7 ]
机构
[1] Univ Teknol MARA UiTM, Fac Med, Dept Internal Med, Sungai Buloh, Selangor Darul, Malaysia
[2] Univ Teknol MARA UiTM, Inst Pathol Lab & Forens Med I PPerForM, Sungai Buloh, Selangor Darul, Malaysia
[3] Int Med Univ, Sch Med, Dept Pharmacol & Therapeut, Kuala Lumpur, Malaysia
[4] Univ Teknol MARA UiTM, Fac Med, Dept Publ Hlth Med, Sungai Buloh, Selangor Darul, Malaysia
[5] MSU Med Ctr, Shah Alam, Selangor Darul, Malaysia
[6] Management & Sci Univ, MSU Clin Ctr Excellence, Shah Alam, Selangor Darul, Malaysia
[7] Univ Teknol MARA UiTM, Fac Med, Inst Med Mol Biotechnol IMMB, Sungai Buloh, Selangor Darul, Malaysia
关键词
Type 2 diabetes mellitus; Diabetic retinopathy; Tissue plasminogen activator (tPA); Plasminogen activator inhibitor-1 (PAI-1); INSULIN-RESISTANCE; OBESITY; PROTEINS; PARAMETERS; PAI-1;
D O I
10.1186/s12886-022-02550-4
中图分类号
R77 [眼科学];
学科分类号
100212 ;
摘要
Background Diabetic retinopathy (DR) is a serious complication of longstanding type 2 diabetes mellitus (T2DM), a leading cause of blindness and visual disability in the world. The aim of this study is to compare the activity of tissue plasminogen activator (tPA) and plasminogen activator inhibitor-1 (PAI-1) in tears and serum of patients with DR and those without DR. Method Among the T2DM patients enrolled in this study, 26 patients had DR (n = 26) while 29 were without DR (n = 29). The blood and tear samples were obtained from all participants. The level of PAI-1 and tPA were measured in both the serum and tears. Anthropometric measurements, HbA1c, renal and lipid profile were also obtained. Results Patients with DR had significantly longer disease duration and higher systolic blood pressure compared to those without DR. Serum PAI-1 level was significantly higher in patients with DR compared to those without DR, 32.72 (IQR 32.52) vs 21.37 (IQR 14.93) ng/mL, respectively (p < 0.05). However, tear PAI-1 were comparable in both groups. Serum and tear tPA levels in both groups were also comparable (p > 0.05). Among patients with DR, there were no significant correlations between tear and serum of both biomarkers. Patients without DR showed a moderate positive correlation between serum and tear tPA levels with a coefficient of 0.363, albeit no statistical significance. Patients with DR demonstrated a significant positive correlation between levels of tears PAI-1 and BMI (r = 0.555, p = 0.026). In the group without DR, there was a statistically significant positive correlation between serum level of PAI-1 with urine albumin creatinine ratio (UACR) (r = 0.501, p = 0.013). Conclusion The present study demonstrated a significantly greater serum PAI-1 levels in patients with DR compared to those without DR. No significant correlations between tears and serum PAI-1 and tPA were observed. Thus, the role of tear biomarkers remains relevant for further investigations.
引用
收藏
页数:8
相关论文
共 50 条
  • [31] Plasminogen activator inhibitor-1 and tissue plasminogen activator and incident AF: Data from the PREVEND study
    Mulder, Bart A.
    Geelhoed, Bastiaan
    van der Harst, Pim
    Spronk, Henri M.
    Van Gelder, Isabelle C.
    Asselbergs, Folkert W.
    Rienstra, Michiel
    INTERNATIONAL JOURNAL OF CARDIOLOGY, 2018, 272 : 208 - 210
  • [32] Plasma tissue plasminogen activator and plasminogen activator inhibitor-1 in hospitalized COVID-19 patients
    Zuo, Yu
    Warnock, Mark
    Harbaugh, Alyssa
    Yalavarthi, Srilakshmi
    Gockman, Kelsey
    Zuo, Melanie
    Madison, Jacqueline A.
    Knight, Jason S.
    Kanthi, Yogendra
    Lawrence, Daniel A.
    SCIENTIFIC REPORTS, 2021, 11 (01)
  • [33] Plasma tissue plasminogen activator and plasminogen activator inhibitor-1 in hospitalized COVID-19 patients
    Yu Zuo
    Mark Warnock
    Alyssa Harbaugh
    Srilakshmi Yalavarthi
    Kelsey Gockman
    Melanie Zuo
    Jacqueline A. Madison
    Jason S. Knight
    Yogendra Kanthi
    Daniel A. Lawrence
    Scientific Reports, 11
  • [34] Polymerization of plasminogen activator inhibitor-1
    Zhou, A
    Faint, R
    Charlton, P
    Dafforn, TR
    Carrell, RW
    Lomas, DA
    JOURNAL OF BIOLOGICAL CHEMISTRY, 2001, 276 (12) : 9115 - 9122
  • [35] Role of tissue-type plasminogen activator and plasminogen activator inhibitor-1 in psychological stress and depression
    Tsai, Shih-Jen
    ONCOTARGET, 2017, 8 (68) : 113258 - 113268
  • [36] Prognostic value of plasminogen activator inhibitor-1 and tissue plasminogen activator in the evaluation of patients with chest pain
    Glynn, T.
    Friedman, S. A.
    Link, C. A.
    Hughes, M.
    Felton, B.
    Ginsberg, D. S.
    Day, D. E.
    ANNALS OF EMERGENCY MEDICINE, 2007, 50 (03) : S78 - S78
  • [37] Plasminogen Activator Inhibitor-1 in Aging
    Yamamoto, Koji
    Takeshita, Kyosuke
    Saito, Hidehiko
    SEMINARS IN THROMBOSIS AND HEMOSTASIS, 2014, 40 (06): : 652 - 659
  • [38] Plasminogen activator inhibitor-1 and the kidney
    Eddy, AA
    AMERICAN JOURNAL OF PHYSIOLOGY-RENAL PHYSIOLOGY, 2002, 283 (02) : F209 - F220
  • [39] PLASMINOGEN-ACTIVATOR INHIBITOR-1
    LOSKUTOFF, DJ
    MIMURO, J
    HEKMAN, C
    THROMBOSIS AND HAEMOSTASIS, 1987, 58 (01) : 534 - 534
  • [40] Gene polymorphisms of tissue plasminogen activator and plasminogen activator inhibitor-1 in patients with antiphospholipid syndrome.
    Yasuda, S
    Tsutsumi, A
    Atsumi, T
    Bertolaccini, ML
    Ichikawa, K
    Khamashta, MA
    Hughes, GRV
    Koike, T
    ARTHRITIS AND RHEUMATISM, 1999, 42 (09): : S371 - S371